Gilbert, J., Lee, J. W., Argiris, A., Haigentz, M., Feldman, L. E., Jang, M., . . . Forastiere, A. A. (2012). Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group.

Gilbert, Jill, Ju Whei Lee, Athanassios Argiris, Missak Haigentz, Lawrence Eric Feldman, Minyoung Jang, Pattatheyil Arun, Carter Van Waes, and Arlene A. Forastiere. Phase II 2-arm Trial of the Proteasome Inhibitor, PS-341 (bortezomib) in Combination With Irinotecan or PS-341 Alone Followed By the Addition of Irinotecan At Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (E1304): A Trial of the Eastern Cooperative Oncology Group. 2012.

Gilbert, Jill, et al. Phase II 2-arm Trial of the Proteasome Inhibitor, PS-341 (bortezomib) in Combination With Irinotecan or PS-341 Alone Followed By the Addition of Irinotecan At Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (E1304): A Trial of the Eastern Cooperative Oncology Group. 2012.